Imperial College London
Alternate

Professor Graham P Taylor

Faculty of Medicine, Department of Infectious Disease

Professor of Human Retrovirology
 
 
 
//

Contact

 

+44 (0)20 7594 3910g.p.taylor Website

 
 
//

Location

 

443Medical SchoolSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Taylor:2018:10.1002/rmv.1970,
author = {Taylor, GP},
doi = {10.1002/rmv.1970},
journal = {Reviews in Medical Virology},
pages = {e1970--e1970},
title = {Human T-Lymphotropic Virus Type 1 infection and solid organ transplantation},
url = {http://dx.doi.org/10.1002/rmv.1970},
volume = {28},
year = {2018}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - HTLV infection appears to be more common among renal transplant candidates than in the related general population. HTLV1associated diseases may occur in carriers who are transplanted but there is insufficient evidence to confirm whether these occur more frequently as a result of the associated immunosuppression. Consequently, preexisting HTLV1 infection should not be considered a contraindication to transplantation.The risk of transmission of HTLV1 through solid organ transplantation from a confirmed infected donor is unknown. There are anecdotes of multiple infections from a single donor. Biologically due to the significant volume of blood and the lack of storage, transmission would be expected to be higher than following blood transfusion. The rate of subsequent disease is unknown, but there are now 11 reports of HAM and 2 of ATL occurring within 4 years of transplantation associated infection. There are insufficient data to know whether the time from infection to onset of disease and the rate of progression differ from transmission through other routes, but early onset and rapid progression is a concern. Responses to enhanced immunosuppression for the treatment of HAM are variable.The risk of HTLV1 associated disease in exchange for a lifesaving major organ transplantation from an infected donor might be considered worth taking by some HTLV1 uninfected patients. Peritransplantation antiretroviral prophylaxis with zidovudine and raltegravir is biologically sound but therapeutically unproven. The risks related to HTLV1 infection appear to preclude the use of any other tissue. All transplant donors should be screened for HTLV1 infection regardless of perceived risk.
AU  - Taylor,GP
DO  - 10.1002/rmv.1970
EP  - 1970
PY  - 2018///
SN  - 1052-9276
SP  - 1970
TI  - Human T-Lymphotropic Virus Type 1 infection and solid organ transplantation
T2  - Reviews in Medical Virology
UR  - http://dx.doi.org/10.1002/rmv.1970
UR  - http://hdl.handle.net/10044/1/56006
VL  - 28
ER  -
Download